PAVmed Reveals First Quarter 2026 Financial Results and Business Progress
PAVmed Inc. (NASDAQ: PAVM), a leading name in diversified medical technologies, has provided a significant business update and reported its financial results for the first quarter of 2026. The company, which is involved in the medical device, diagnostics, and digital health sectors, showed notable advancements particularly in its core operations. In a detailed announcement made on May 15, 2026, the company outlined its path toward growth and innovation with key highlights that include developments across its subsidiaries, Veris Health Inc. and Lucid Diagnostics Inc.
PAVmed's Chairman and CEO, Dr. Lishan Aklog, emphasized the strengthening of the company’s capital structure and its simplified framework, which is set to enhance execution across various business segments. He stated, "PAVmed now has a significantly simplified capital structure and strengthened balance sheet, positioning the Company to focus on execution across our core businesses and evaluate additional asset acquisition opportunities aligned with our long-term growth strategy."
PAVmed is actively advancing its relaunched medical device portfolio, which includes innovative products such as the PortIO implantable device for intraosseous vascular access and endoscopic esophageal imaging technology licensed from Duke University. Joseph Virgilio is at the helm of leading this portfolio, applying his extensive experience in scaling medtech businesses.
For the first quarter ended March 31, 2026, PAVmed recorded operating expenses of approximately $8.1 million, with a net loss attributable to stockholders of about $7.0 million or $(4.42) per share on a diluted basis. Conversely, the non-GAAP adjusted net loss was reported at approximately $1.9 million or $(1.17) per share. As of the end of the first quarter, the company had cash reserves of $6.5 million, significantly improving from $1.5 million at the end of the previous year.
Veris Health is committed to enhancing personalized cancer care through its remote patient monitoring solutions that utilize implantable sensors. The company is advancing its implantable physiological monitor, with presubmission activities and testing set to begin shortly in preparation for an FDA submission. Their collaborations with Ohio State University's James Cancer Hospital continue to yield positive feedback, further solidifying their commercial engagement.
Lucid Diagnostics has made strides in its commercial trajectory by reporting $1.3 million in revenues from its EsoGuard® Esophageal DNA Test for the first quarter and processing over 3,177 tests. The company fortified its balance sheet through a successful public offering, raising about $17 million, which sets the stage for its expansion into 2027. At the recently held Digestive Disease Week, Lucid's presence was marked by significant engagement and a preview of major clinical guidelines recommending its products.
Looking ahead, PAVmed is expected to host a conference call and webcast on May 15, 2026, at 8:30 AM EDT for investors and stakeholders to discuss the Q1 results in detail. This event highlights PAVmed's dedication to transparency and continuous dialogue with its shareholders.
In an evolving healthcare landscape, PAVmed's commitment to innovation in medical technology is evident as it continues to explore additional acquisition opportunities and strengthen its product offerings. The company aims to further enhance its market position while positively impacting patient care outcomes across its operational domains. For further inquiries and updates, stakeholders can check PAVmed's official website for the replay of the recent conference call and ongoing developments.
Business Overview
PAVmed's Chairman and CEO, Dr. Lishan Aklog, emphasized the strengthening of the company’s capital structure and its simplified framework, which is set to enhance execution across various business segments. He stated, "PAVmed now has a significantly simplified capital structure and strengthened balance sheet, positioning the Company to focus on execution across our core businesses and evaluate additional asset acquisition opportunities aligned with our long-term growth strategy."
PAVmed is actively advancing its relaunched medical device portfolio, which includes innovative products such as the PortIO implantable device for intraosseous vascular access and endoscopic esophageal imaging technology licensed from Duke University. Joseph Virgilio is at the helm of leading this portfolio, applying his extensive experience in scaling medtech businesses.
Financial Results
For the first quarter ended March 31, 2026, PAVmed recorded operating expenses of approximately $8.1 million, with a net loss attributable to stockholders of about $7.0 million or $(4.42) per share on a diluted basis. Conversely, the non-GAAP adjusted net loss was reported at approximately $1.9 million or $(1.17) per share. As of the end of the first quarter, the company had cash reserves of $6.5 million, significantly improving from $1.5 million at the end of the previous year.
Highlights from Subsidiaries
Veris Health
Veris Health is committed to enhancing personalized cancer care through its remote patient monitoring solutions that utilize implantable sensors. The company is advancing its implantable physiological monitor, with presubmission activities and testing set to begin shortly in preparation for an FDA submission. Their collaborations with Ohio State University's James Cancer Hospital continue to yield positive feedback, further solidifying their commercial engagement.
Lucid Diagnostics
Lucid Diagnostics has made strides in its commercial trajectory by reporting $1.3 million in revenues from its EsoGuard® Esophageal DNA Test for the first quarter and processing over 3,177 tests. The company fortified its balance sheet through a successful public offering, raising about $17 million, which sets the stage for its expansion into 2027. At the recently held Digestive Disease Week, Lucid's presence was marked by significant engagement and a preview of major clinical guidelines recommending its products.
Upcoming Developments
Looking ahead, PAVmed is expected to host a conference call and webcast on May 15, 2026, at 8:30 AM EDT for investors and stakeholders to discuss the Q1 results in detail. This event highlights PAVmed's dedication to transparency and continuous dialogue with its shareholders.
In an evolving healthcare landscape, PAVmed's commitment to innovation in medical technology is evident as it continues to explore additional acquisition opportunities and strengthen its product offerings. The company aims to further enhance its market position while positively impacting patient care outcomes across its operational domains. For further inquiries and updates, stakeholders can check PAVmed's official website for the replay of the recent conference call and ongoing developments.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.